Background:The use of distinct drugs and techniques for establishing balanced anesthesia protocols has shown promising results in birds. The techniques of locoregional block can be incorporated to these protocols, thereby providing intra-and post-operative analgesia and reducing the requirement for general anesthesia. Additionally, the use of neurostimulators increases the chances of success and reduces the risk of toxicity; however, there are limited reports in the literature of its applicability in wild birds. Therefore, the aim of this study was to describe the brachial plexus block technique guided using a neurolocalizer in a striped owl (Asio clamator) submitted for right wing amputation. Case: A striped owl weighing 400 g with a history of exposed fracture of the right wing was supplied by the clinical sector at the Veterinarian Hospital of the Federal University of Bahia. Following hydration and stabilization of vital signs, the animal was referred to the surgical center for amputation of the limb. Dexmedetomidine (10 µg.kg −1 IM) was administered as premedication, and after 20 min, anesthetic induction was performed using sevoflurane (FiO 2 = 100%) via a mask followed by maintenance using the same drug. The animal was positioned in a left lateral decubitus position with access to the brachial plexus determined by palpation and identification of the border of the following muscles: pectoral, cranial branch of the brachial biceps, and dorsal branch of the ventral serratus. The brachial plexus nerves are situated in the subcutaneous site craniodorsal to the axillary depression. For the block, a neurolocalizer was used, fixing the positive electrode to approximately 5 cm from the needle insertion site (21G × 2'") in the axillary depression, which remained connected to the neurostimulator by the second electrode. At first, the needle was attached to the peripheral nerve stimulator using a pulse frequency of 1 Hz with an impulse duration of 0.1 ms and initial current of 1 mA. The needle was advanced in the direction of the nerve plexus until it was observed that muscular contractions and movement in the limb were blocked, gradually decreasing the contractions, which disappeared at a current of 0.3 mA. At this juncture, after verifying the absence of blood on aspiration, ropivacaine was injected (2 mg/kg) with a latency period of 20 min. Data were recorded via monitoring of vital signs (DigicareLifeWindowLW9xVet), recording an average hearth rate of 140 ± 9.84 bpm, respiratory rate of 30 ± 4.18 mpm, oxyhemoglobin saturation of 99%, end-tidal carbon dioxide of 26 ± 1.98 mmHg, and temperature of 37.4°C ± 0.11°C over the course of 20 min of the surgical procedure. No movements were observed in response to pain stimuli, and the animal exhibited normal recovery, free of excitation or signs of pain. Discussion: Considering the imprecise history regarding fracture time as well as the lack of specific tests to clearly elucidate the condition of this animal, selective and safe drugs were selected including dexmedetomidin...
RESUMO Objetivou-se comparar os efeitos fisiológicos, analgésicos e sobre a taxa de infusão de propofol, decorrentes da anestesia epidural com lidocaína, associada ao tramadol ou à dexmedetomidina, em felinas submetidas à ovariosalpingohisterectomia (OSH). Para tal, 16 felinas hígidas foram pré-tratadas com acepromazina 0,08mg/kg/IM, utilizando-se propofol para a indução (dose-efeito) e manutenção anestésicas. Após indução, as gatas foram aleatoriamente distribuídas em dois grupos (n=8), designados: grupo lidocaína-tramadol (GLT), tratado com lidocaína (3,0mg/kg) associada ao tramadol (2,0mg/kg); e grupo lidocaína-dexmedetomidina (GLD), tratado com lidocaína (3,0mg/kg) associada à dexmedetomidina (2µg/kg), pela via epidural. Durante a OSH, a infusão de propofol foi aumentada ou reduzida, objetivando-se manutenção de plano anestésico cirúrgico. Foram avaliados os parâmetros: f, FC, SPO2, EtCO2, PAS, PAD, PAM, T°C, nos períodos pré (M1) e transoperatórios (M2 a M7); a taxa mínima de propofol necessária; o tempo de recuperação anestésica e a qualidade da analgesia pós-cirúrgica durante seis horas. Ambos os tratamentos garantiram baixas taxas mínimas de infusão de propofol, todavia o uso da dexmedetomidina resultou em bradicardia inicial, elevação da pressão arterial, maior tempo de recuperação e menor qualidade analgésica, quando comparada ao tramadol.
Objetivou-se com esse trabalho avaliar o uso do anestésico alfaxalona associado à meperidina e midazolam para o procedimento de desobstrução uretral em um gato com doença do trato urinário inferior felino (DTUIF), analisando as qualidades de indução e recuperação, assim como as alterações fisiológicas. Um felino macho, quatro anos de idade, 3.1 Kg, castrado, foi atendido no setor de emergência do Hospital Veterinário da Universidade Federal Rural do Semi-árido com histórico de estrangúria, abdome distendido e vesícula urinária repleta, sendo diagnosticado com DTUIF obstrutiva. Para o procedimento de desobstrução uretral a MPA foi instituída com meperidina 3mg/Kg por via intramuscular (IM), dez minutos após, procedeu-se a indução anestésica: 0,4mg/ Kg de midazolam seguido de 2mg/Kg de alfaxalona, ambos diluídos em água de injeção, dispostos separadamente em seringas individuais, e administrados pela via intravenosa (IV). A alfaxalona foi administrado lentamente, contabilizando 1 minuto para total fornecimento. Foram avaliadas a frequência cardíaca (FC), frequência respiratória (f), temperatura retal (TR), pressão arterial sistólica (PAS), média (PAM), diastólica (PAD) e hemogasometria venosa, antes, durante e após o procedimento anestésico. A alfaxalona em associação com o midazolam produziu perda rápida da consciência, do reflexo de deglutição e intenso relaxamento muscular, bem como boa qualidade de indução e recuperação. O protocolo utilizado produziu mínimas anormalidades clinico patológicas, sem alterações importantes nos parâmetros cardíacos e respiratórios durante todo o procedimento, com manutenção da pressão arterial. Portanto, o anestésico alfaxalona foi considerado seguro para o procedimento de desobstrução uretral em gato macho com DTUIF.
The aim of this study was to compare the effects of midazolam-ketamine alone or in combination with dexmedetomidine or tramadol in a constant rate infusion (CRI) on the minimum infusion rate (MIR) of propofol and the cardiorespiratory function in cats undergoing an ovariohysterectomy (OH). This was a prospective, randomised, blinded clinical study. Twenty-four healthy female mixed-breed cats were premedicated with ketamine and midazolam. Propofol was used for the induction and maintenance of the anaesthesia (starting at 18 mg/kg/h). Cats were assigned to groups (n = 8) to receive one of the following intravenous treatments: midazolam-ketamine group (MKG; ketamine 0.6 mg/kg/h); midazolam-ketamine-dexmedetomidine group [MKDG; ketamine 0.6 mg/kg/h and dexmedetomidine loading dose (LD) 1 mg/kg, CRI 1 mg/kg/h)] or midazolam-ketamine-tramadol group [MKTG; ketamine 0.6 mg/kg/h and tramadol (LD 2 mg/kg, CRI 1 mg/kg/h)]. During the OH, the propofol infusion was adjusted based on the clinical signs to maintain adequate anaesthetic depth. Selected variables were measured before (T0) and after (T1) the anaesthesia induction and during six surgical time points (T2–T7). The mean arterial pressure was higher and the heart rate was lower in MKDG at T1 (than in MKG and MKTG). The mean ± SD MIR of propofol were 17.4 ± 3.2, 15.0 ± 2.8 and 12.6 ± 3.5 mg/kg/h for MKG, MKTG, and MKDG, respectively. We conclude that, compared to midazolam-ketamine alone, midazolam-ketamine-tramadol and midazolam-ketamine-dexmedetomidine reduced the MRI of propofol by 13.8% and 27.5%, respectively, without significant changes in the selected indicators.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.